According to Tiantan Biotech's announcement, net profit attributable to owners of the parent company is expected to be 305 million yuan for the first half year of 2026, a year-on-year decrease of 327 million yuan, a decrease of about 51.75%; deducted non-net profit is 291 million yuan, a year-on-year decrease of 327 million yuan, a decrease of about 52.89%. Net profit for the same period last year was 633 million yuan. The pre-reduction in performance was mainly due to increased industry competition, lower product prices, and adjustments to value-added tax policies for biological products due to factors such as medical insurance fee control.

According to Tiantan Biotech's announcement, net profit attributable to owners of the parent company is expected to be 305 million yuan for the first half year of 2026, a year-on-year decrease of 327 million yuan, a decrease of about 51.75%; deducted non-net profit is 291 million yuan, a year-on-year decrease of 327 million yuan, a decrease of about 52.89%. Net profit for the same period last year was 633 million yuan. The pre-reduction in performance was mainly due to increased industry competition, lower product prices, and adjustments to value-added tax policies for biological products due to factors such as medical insurance fee control.